Drug Trial Radar · NCT06532279
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
98
Planned (sponsor's estimate)
Start
Jun 23, 2025
Primary completion
Jan 1, 2027
Study completion Jan 1, 2032
Sponsor
- Lead sponsor
- NRG OncologyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Supportive care
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial compares the effectiveness of adding BMX-001 to usual symptom management versus usual symptom management alone for reducing oral mucositis in patients who are receiving chemoradiation for head and neck cancer. Oral mucositis (inflammation and mouth sores) is a common side effect of chemoradiation that can cause pain and difficulty swallowing. Usual management of these side effects typically consists of using mouth rinses and pain medications during treatment and for several weeks after completion of treatment. BMX-001 neutralizes harmful substances in the body, preventing damage to macromolecules such as DNA and minimizes free radical-related toxicity in normal tissues. Adding BMX-001 to usual symptom management may be more effective than usual symptom management alone at reducing oral mucositis in patients receiving chemoradiation for head and neck cancer.
Conditions
- Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Head and Neck Squamous Cell Carcinoma
- Hypopharyngeal Squamous Cell Carcinoma
- Laryngeal Squamous Cell Carcinoma
- Nasopharyngeal Squamous Cell Carcinoma
- Oral Cavity Squamous Cell Carcinoma
- Oropharyngeal Squamous Cell Carcinoma
- Stage 0 Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
- Stage 0 Hypopharyngeal Carcinoma AJCC v8
- Stage 0 Nasopharyngeal Carcinoma AJCC v8
- Stage 0 Oropharyngeal (p16-Negative) Carcinoma AJCC v8
- Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
- Stage I Hypopharyngeal Carcinoma AJCC v8
- Stage I Laryngeal Cancer AJCC v8
- Stage I Lip and Oral Cavity Cancer AJCC v8
- Stage I Nasopharyngeal Carcinoma AJCC v8
- Stage I Oropharyngeal (p16-Negative) Carcinoma AJCC v8
- Stage II Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
- Stage II Hypopharyngeal Carcinoma AJCC v8
- Stage II Laryngeal Cancer AJCC v8
- Stage II Lip and Oral Cavity Cancer AJCC v8
- Stage II Nasopharyngeal Carcinoma AJCC v8
- Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8
- Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
- Stage III Hypopharyngeal Carcinoma AJCC v8
- Stage III Laryngeal Cancer AJCC v8
- Stage III Lip and Oral Cavity Cancer AJCC v8
- Stage III Nasopharyngeal Carcinoma AJCC v8
- Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8
- Stage IVA Hypopharyngeal Carcinoma AJCC v8
- Stage IVA Laryngeal Cancer AJCC v8
- Stage IVA Lip and Oral Cavity Cancer AJCC v8
- Stage IVA Nasopharyngeal Carcinoma AJCC v8
- Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8
- Stage IVB Hypopharyngeal Carcinoma AJCC v8
- Stage IVB Laryngeal Cancer AJCC v8
- Stage IVB Lip and Oral Cavity Cancer AJCC v8
- Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
- Stomatitis
Interventions
Best PracticeOther
Receive usual symptom management
Biospecimen CollectionProcedure
Undergo collection of blood, serum, and/or plasma samples
CisplatinDrug
Given cisplatin
Computed TomographyProcedure
Undergo CT
Image Guided Radiation TherapyRadiation
Undergo image-guided radiation therapy
Intensity-Modulated Radiation TherapyRadiation
Undergo intensity-modulated radiation therapy
Magnetic Resonance ImagingProcedure
Undergo MRI
MnSOD Mimetic BMX-001Drug
Given SC
Placebo AdministrationDrug
Given SC
Questionnaire AdministrationOther
Ancillary studies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of severe oral mucositis (SOM)Time frame: From start of radiation through 4 weeks after completion of study treatment
Locations
153 sites in 1 country. Site status is shown where the registry gives one.
Arizona Center for Cancer Care - Gilbert
Gilbert, Arizona · Recruiting
Arizona Center for Cancer Care-Peoria
Peoria, Arizona · Recruiting
Arizona Center for Cancer Care - Phoenix
Phoenix, Arizona · Recruiting
Arizona Center for Cancer Care - Scottsdale
Scottsdale, Arizona · Recruiting
Arizona Center for Cancer Care-Surprise
Surprise, Arizona · Recruiting
Arizona Center for Cancer Care
Tempe, Arizona · Recruiting
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
Jonesboro, Arkansas · Recruiting
Keck Medicine of USC Buena Park
Buena Park, California · Suspended
UC San Diego Health System - Encinitas
Encinitas, California · Recruiting
UC San Diego Moores Cancer Center
La Jolla, California · Recruiting
Los Angeles General Medical Center
Los Angeles, California · Suspended
USC / Norris Comprehensive Cancer Center
Los Angeles, California · Suspended
USC Norris Oncology/Hematology-Newport Beach
Newport Beach, California · Suspended
UC San Diego Medical Center - Hillcrest
San Diego, California · Recruiting
Shaw Cancer Center
Edwards, Colorado · Recruiting
George Washington University Medical Center
Washington D.C., District of Columbia · Recruiting
Sarasota Memorial Hospital-Venice
N. Venice, Florida · Recruiting
Moffitt Cancer Center at SouthShore
Ruskin, Florida · Recruiting
Florida Cancer Specialists - Sarasota
Sarasota, Florida · Recruiting
Florida Cancer Specialists - Sarasota Downtown
Sarasota, Florida · Recruiting
Sarasota Memorial Hospital
Sarasota, Florida · Recruiting
Sarasota Memorial Health Care Center at University Parkway
Sarasota, Florida · Recruiting
Moffitt Cancer Center-International Plaza
Tampa, Florida · Recruiting
Moffitt Cancer Center - McKinley Campus
Tampa, Florida · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
Florida Cancer Specialists - Venice Pinebrook
Venice, Florida · Recruiting
Moffitt Cancer Center at Wesley Chapel
Wesley Chapel, Florida · Recruiting
OSF Saint Joseph Medical Center
Bloomington, Illinois · Recruiting
Illinois CancerCare-Bloomington
Bloomington, Illinois · Recruiting
Illinois CancerCare-Canton
Canton, Illinois · Recruiting
Northwestern University
Chicago, Illinois · Recruiting
Carle at The Riverfront
Danville, Illinois · Recruiting
Northwestern Medicine Cancer Center Kishwaukee
DeKalb, Illinois · Recruiting
Carle Physician Group-Effingham
Effingham, Illinois · Recruiting
Illinois CancerCare-Eureka
Eureka, Illinois · Recruiting
Illinois CancerCare-Galesburg
Galesburg, Illinois · Recruiting
Northwestern Medicine Cancer Center Delnor
Geneva, Illinois · Recruiting
Illinois CancerCare-Kewanee Clinic
Kewanee, Illinois · Recruiting
Illinois CancerCare-Macomb
Macomb, Illinois · Recruiting
Carle Physician Group-Mattoon/Charleston
Mattoon, Illinois · Recruiting
Showing 40 of 153 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.